Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29123704 | 0.77 | HRH1 (0.44) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL10383999 | 0.74 | CA3 (0.43) | SLC6A4HTR2A | |
| SCHEMBL10383998 | 0.74 | CA3 (0.43) | SLC6A4HTR2A | |
| SCHEMBL2838303 | 0.71 | KEAP1 (0.46) | — | |
| SCHEMBL4436450 | 0.71 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL25549445 | 0.70 | IDO1 (0.37) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL10338205 | 0.69 | ALOX5AP (0.31) | — | |
| SCHEMBL2689127 | 0.69 | ALDH1A1 (0.52) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21358033 | 0.69 | GABRA1 (0.56) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30536248 | 0.69 | ALDH1A1 (0.52) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423168-B2 | Reacting allyl starting compound with oxygen nucleophilic agent in presence of transition metal catalyst and monodentate phosphite | MITSUBISHI CHEMICAL CORPORATION (JP) | 2008-09-09 | — | — | US | disclosed |
| US-7241857-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7173157-B2 | Method for producing an allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7119222-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040092777-A1 | Method for producing allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | SLC6A4 4138/4885SLC6A2 4522/4885SLC6A3 4204/4885 |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | SLC6A4 4138/4885SLC6A2 4522/4885SLC6A3 4204/4885 |
| US-20040092777-A1 | Method for producing allyl compound | CCNT1, APEX1, REV1 | SLC6A4 4659/4885SLC6A2 4714/4885SLC6A3 4185/4885 |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | CCNT1, AOC3, ATL3 | SLC6A4 4217/4885SLC6A2 4344/4885SLC6A3 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.